Health Care [ 11/12 ] | Biotechnology [ 53/76 ]
NASDAQ | Common Stock
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 1, 24 | -3.33 Increased by +8.01% | -3.39 Increased by +1.77% |
| May 2, 24 | -3.07 Decreased by -1.72 K% | -3.58 Increased by +14.25% |
| Feb 22, 24 | 0.55 Decreased by -84.76% | -0.97 Increased by +156.70% |
| Nov 2, 23 | -9.53 Decreased by -476.68% | -1.93 Decreased by -393.78% |
| Aug 3, 23 | -3.62 Decreased by -169.08% | -4.04 Increased by +10.40% |
| May 4, 23 | 0.19 Decreased by -97.79% | -1.77 Increased by +110.73% |
| Feb 23, 23 | 3.61 Decreased by -68.02% | 4.68 Decreased by -22.86% |
| Nov 3, 22 | 2.53 Decreased by -67.14% | 3.29 Decreased by -23.10% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 167.00 M Decreased by -91.03% | -1.18 B Decreased by -1.59 K% | Decreased by -703.59% Decreased by -16.68 K% |
| Dec 31, 23 | 2.81 B Decreased by -44.67% | 217.00 M Decreased by -85.19% | Increased by +7.71% Decreased by -73.23% |
| Sep 30, 23 | 1.83 B Decreased by -43.14% | -3.63 B Decreased by -448.03% | Decreased by -198.25% Decreased by -712.05% |
| Jun 30, 23 | 344.00 M Decreased by -92.47% | -1.38 B Decreased by -162.81% | Decreased by -401.16% Decreased by -933.73% |
| Mar 31, 23 | 1.86 B Decreased by -68.65% | 79.00 M Decreased by -97.84% | Increased by +4.24% Decreased by -93.11% |
| Dec 31, 22 | 5.08 B Decreased by -26.84% | 1.47 B Decreased by -69.91% | Increased by +28.82% Decreased by -58.87% |
| Sep 30, 22 | 3.22 B Decreased by -33.32% | 1.04 B Decreased by -68.71% | Increased by +32.39% Decreased by -53.07% |
| Jun 30, 22 | 4.57 B Increased by +8.33% | 2.20 B Decreased by -20.97% | Increased by +48.12% Decreased by -27.05% |